Search our Database of Scientific Publications and Authors

I’m looking for a

    2742 results match your criteria Thyroid Anaplastic Carcinoma

    1 OF 55

    Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.
    Oncol Lett 2017 Dec 26;14(6):6485-6496. Epub 2017 Sep 26.
    Division of Pathology Diagnostic Services, Cytology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
    Despite considerable advances in the understanding of thyroid gland biology, correctly diagnosing thyroid nodules and treating high-grade thyroid carcinoma remains challenging. Cancer/testis (CT) antigens have emerged as potential diagnostic tools as well as targets of potential cancer vaccinations. In the present study, a total of 117 patients who underwent surgical therapy for thyroid disease were available for analysis. Read More

    Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma.
    Thyroid 2017 Nov 22. Epub 2017 Nov 22.
    University of Texas M.D. Anderson Cancer Center, Endocrine Neoplasia and Hormonal Disorders , 1515 Holcombe Blvd, unit 1461 , Houston, Texas, United States , 77030 ;
    Background: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis despite systemic cytotoxic chemotherapy. Our objective was to study the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial.

    Methods: This is a retrospective review from April 2015 to May 2016 at a single academic institution where we studied 16 ATC patients receiving targeted therapy outside of a clinical trial. Read More

    Squamous Cell Carcinoma of the Thyroid as a Result of Anaplastic Transformation from BRAF-Positive Papillary Thyroid Cancer.
    Case Rep Oncol Med 2017 12;2017:4276435. Epub 2017 Oct 12.
    Department of Hematology Oncology, SUNY Upstate Medical University, Syracuse, NY 13205, USA.
    Papillary thyroid carcinoma (PTC) is the most common malignant neoplasm of the thyroid. Majority of the PTC carries an excellent prognosis. However, patients with tall cell variant (TCV) of papillary thyroid carcinoma have a worse prognosis than those with the classic variant. Read More

    Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).
    Oncotarget 2017 Oct 24;8(49):84743-84760. Epub 2017 Sep 24.
    Laboratory of human thyroid cancers preclinical and translational research, Division of Experimental Pathology, Cancer Research Institute, Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
    Purpose: Papillary thyroid carcinoma (PTC) is the most frequent endocrine tumor. BRAF(V600E) represents the PTC hallmark and is targeted with selective inhibitors (e.g. Read More

    The Role of Tracheostomy in Anaplastic Thyroid Carcinoma.
    World J Oncol 2015 Feb 14;6(1):262-264. Epub 2015 Feb 14.
    Department of Otolaryngology-Head & Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, 600 Tianhe Road, Guangzhou, Guangdong, 510630, China.
    Even though management of thyroid cancer is generally standardized and has an overall excellent long-term outcome, anaplastic thyroid cancer (ATC) continues to be a major diagnostic and therapeutic challenge. ATC is an uncommon thyroid malignancy with a poor prognosis. American Thyroid Association guidelines acknowledge the complexity of airway management in these patients. Read More

    Partially cystic thyroid nodules in ultrasound-guided fine needle aspiration: Prevalence of thyroid carcinoma and ultrasound features.
    Medicine (Baltimore) 2017 Nov;96(46):e8689
    aDepartment of Ultrasound bDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
    Partially cystic thyroid nodules (PCTNs) are common on ultrasound (US). However, there are insufficient data on the prevalence of thyroid carcinoma among such nodules. The purpose of this study was thus to evaluate the prevalence and differentiation of partially cystic thyroid cancers in US-guided fine needle aspiration (FNA). Read More

    FNA diagnosis of poorly differentiated thyroid carcinoma. A review of the recent literature.
    Cytopathology 2017 Dec 2;28(6):467-474. Epub 2017 Nov 2.
    Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
    Poorly differentiated thyroid carcinoma (PDTC) is a follicular cell-derived tumour that was recognised as a distinct entity by the World Health Organisation in 2004. The natural history and pathological features of PDTC are reported to be intermediate between those of well-differentiated and undifferentiated (anaplastic) thyroid carcinomas. Preoperative identification of PDTC could facilitate better initial patient management in many cases, namely more extensive surgery, without any delay. Read More

    Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
    CA Cancer J Clin 2017 Nov 1. Epub 2017 Nov 1.
    Endochrinologist, Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
    Answer questions and earn CME/CNE This is a review of the major changes in the American Joint Committee on Cancer staging manual, eighth edition, for differentiated and anaplastic thyroid carcinoma. All patients younger than 55 years have stage I disease unless they have distant metastases, in which case, their disease is stage II. In patients aged 55 years or older, the presence of distant metastases confers stage IVB, while cases without distant metastases are further categorized based on the presence/absence of gross extrathyroidal extension, tumor size, and lymph node status. Read More

    High-resolution proteomics and metabolomics in thyroid cancer: Deciphering novel biomarkers.
    Crit Rev Clin Lab Sci 2017 Oct 30:1-12. Epub 2017 Oct 30.
    d Proteomic Unit , Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca (IMIB-Arrixaca), Universidad de Murcia , Murcia , Spain.
    The incidence of thyroid cancer (TC) - the most common endocrine malignancy - has been increasing sharply since the mid-1990s. The rate of TC incidence in both men and women has been faster than any other cancer. Both improved diagnoses (i. Read More

    Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance.
    Hum Pathol 2017 Oct 24. Epub 2017 Oct 24.
    Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Electronic address:
    CD20 is the first line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant CD20 expression has been described in a small series of papillary thyroid carcinomas (PTC). We aimed to evaluate CD20 immunoexpression and to perform clinicopathologic correlation in a large set of thyroid tumors, including a cohort of high-grade thyroid cancer. Read More

    Anaplastic Thyroid Carcinoma Treated with Lenvatinib.
    Kurume Med J 2017 Oct 20. Epub 2017 Oct 20.
    Department of Otorhinolaryngology-Head and Neck Surgery, School of Medicine, University of Occupational and Environmental Health.
    Objective: We report a case of anaplastic thyroid carcinoma (ATC) with local recurrence and distant metastasis that responded very well to treatment with lenvatinib, a new molecular-targeted anticancer drug.

    Case Report: A 91-year-old Japanese woman presented with a 5-month history of a painless mass in her left anterior neck. She had a past history of total thyroidectomy and neck dissection for papillary carcinoma of the thyroid. Read More

    Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Thyroid 2017 Nov 10. Epub 2017 Nov 10.
    1 Department of Internal Medicine IV, University Hospital of Munich , LMU Munich, Munich, Germany .
    Background: Anaplastic thyroid carcinoma (ATC), the most aggressive form of thyroid cancer, is unresponsive to radioiodine therapy. The current study aimed to extend the diagnostic and therapeutic application of radioiodine beyond the treatment of differentiated thyroid cancer by targeting the functional sodium-iodide symporter (NIS) to ATC.

    Methods: The study employed nanoparticle vectors (polyplexes) based on linear polyethylenimine (LPEI), shielded by polyethylene glycol (PEG) and coupled to the synthetic peptide GE11 as an epidermal growth factor receptor (EGFR)-specific ligand in order to target a NIS-expressing plasmid (LPEI-PEG-GE11/NIS) to EGFR overexpressing human thyroid carcinoma cell lines. Read More

    Anaplastic thyroid cancer and hyperfractionated accelerated radiotherapy (HART) with and without surgery.
    Eur Arch Otorhinolaryngol 2017 Dec 10;274(12):4203-4209. Epub 2017 Oct 10.
    Division of Laboratory Medicine, Department of Pathology, Oslo University Hospital, Box 4953, 0424, Oslo, Norway.
    Anaplastic carcinoma of the thyroid gland (ATC) is one of the most aggressive cancers in humans. With insufficient treatment, the disease most often leads to death in suffocation. From 2002, our treatment strategy has been hyperfractionated accelerated radiotherapy (HART) with high doses (64 Gy) to the neck, followed by surgery 4-8 weeks later if feasible, with the aim to gain control in the neck. Read More

    Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Invest New Drugs 2017 Oct 11. Epub 2017 Oct 11.
    Department of Medical Oncology, Kishiwada City Hospital, 1001 Gakuhara, Kishiwada, Osaka, 596-8501, Japan.
    Lenvatinib, a novel potent multikinase inhibitor, was approved for the treatment of radioiodine-refractory differentiated thyroid cancer based on results from phase III trial (SELECT study). Thyroid cancer is a diverse disease that includes anaplastic thyroid cancer (ATC), which the most aggressive form of the disease, although it accounts for <2% of all thyroid cancers. Current treatments for ATC have limited efficacy. Read More

    Sunitinib in the treatment of thyroid cancer.
    Curr Med Chem 2017 Oct 6. Epub 2017 Oct 6.
    Department of Clinical and Experimental Medicine, University of Pisa, Via Savi, 10, I-56126, Pisa. Italy.
    Background: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors. Read More

    Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes.
    Mol Diagn Ther 2017 Oct 6. Epub 2017 Oct 6.
    Cellular and Molecular Endocrine Research Center (CMERC), Research Institute for Endocrine Sciences of Shahid Beheshti University of Medical Sciences, 19395-4763, Tehran, Iran.
    Thyroid carcinoma (TC) is the most frequent malignant neoplasm of the endocrine system. Molecular methods for diagnosis of invasive thyroid disease can be effectively adopted. Epigenetic factors play an important role in the diversity patterns of gene expression and the phenotypic and biological characteristics of TC subtypes. Read More

    Patterns of Thyroid Cancers in Southeastern Nigeria: A 15 Year Histopathologic Review (2000-2014).
    J Clin Diagn Res 2017 Aug 1;11(8):EC16-EC19. Epub 2017 Aug 1.
    Senior Lecturer/Consultant, Department of Radiation Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.
    Introduction: Thyroid Cancer (TC) continues to be the most common endocrine cancer with a worldwide increase in incidence over the last three decades. This trend has been reported in all continents except Africa, where detection is adjudged to be insufficient, making it imperative for us to re-evaluate the patterns in our environment.

    Aim: To determine the patterns of TCs in Southeastern Nigeria. Read More

    EIF1AX Mutation in a Patient with Hürthle Cell Carcinoma.
    Endocr Pathol 2017 Sep 30. Epub 2017 Sep 30.
    Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, 925 Chestnut Street 6th Floor, Philadelphia, PA, 19107, USA.
    The EIF1AX gene is a novel cancer gene that has been reported in the tumorigenesis of papillary thyroid carcinoma, follicular variant papillary thyroid carcinoma, and anaplastic thyroid carcinoma. A 71-year-old woman presented with a right thyroid mass, which was follicular neoplasm on cytology. The fine needle aspirate of the nodule was examined by next-generation sequencing and found to harbor EIF1AX and TP53 mutations. Read More

    [Resection of recurrent neck cancers with replacement of the carotid artery].
    J Med Vasc 2017 Oct 30;42(5):282-289. Epub 2017 Aug 30.
    Service de chirurgie vasculaire, université de Poitiers, CHU de Poitiers, 2, rue de la Milétrie, 86021 Poitiers cedex, France.
    Objectives: The management of patients with recurrent neck cancer invading the carotid artery is controversial. The aim of this study was to evaluate the overall survival and healthy survival years (QALY) as well as the patency of carotid revascularization after enbloc tumor resection followed by complementary radiotherapy.

    Methods: From 2000 to 2016, 42 consecutive patients with recurrent neck cancer invading the carotid artery underwent resection of the tumor associated with reconstruction of the carotid artery with a PTFE prosthesis (n=31) or with a saphenous vein graft (n=11). Read More

    Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors.
    J Clin Endocrinol Metab 2017 Nov;102(11):4089-4099
    Department of Urology, Faculty of Medicine, UNESP, São Paulo State University, Botucatu 18618-970, SP, Brazil.
    Context: Even though the majority of well-differentiated thyroid carcinoma (WDTC) is indolent, a number of cases display an aggressive behavior. Cumulative evidence suggests that the deregulation of DNA methylation has the potential to point out molecular markers associated with worse prognosis.

    Objective: To identify a prognostic epigenetic signature in thyroid cancer. Read More

    Role of Dicer1 in thyroid cell proliferation and differentiation.
    Cell Cycle 2017 Sep 21:1-8. Epub 2017 Sep 21.
    a Istituto per l'Endocrinologia e l'Oncologia Sperimentale (IEOS) "G. Salvatore", Consiglio Nazionale delle Ricerche (CNR), c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II" , Naples , Italy.
    DICER1 plays a central role in the biogenesis of microRNAs and it is important for normal development. Altered microRNA expression and DICER1 dysregulation have been described in several types of tumors, including thyroid carcinomas. Recently, our group identified a new somatic mutation (c. Read More

    Berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via PI3K-AKT and MAPK signaling pathways.
    Biomed Pharmacother 2017 Nov 18;95:1225-1231. Epub 2017 Sep 18.
    Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, China. Electronic address:
    Berberine, an important natural isoquinoline alkaloid from traditional Chinese medicine, is reported to exhibit multiple pharmacological properties, including anti-microbial, anti-diabetes, anti-obesity, anti-inflammatory and anti-carcinogenic activities. Although studies have shown that a wide range of carcinoma cells could be inhibited by berberine, few studies involved thyroid carcinoma. We therefore examined the effect of berberine on papillary thyroid carcinoma (PTC, the most common subtype) and anaplastic thyroid carcinoma (ATC, the most malignant and aggressive subtype). Read More

    Cytological Diagnosis of an Uncommon High Grade Malignant Thyroid Tumour: A Case Report.
    J Clin Diagn Res 2017 Jul 1;11(7):ED03-ED05. Epub 2017 Jul 1.
    Senior Resident, Department of Pathology, PGIMER, Dr RML Hospital, New Delhi, India.
    Anaplastic Thyroid Carcinoma (ATC) is a relatively uncommon highly malignant tumour originating from the follicular cells of thyroid gland having poor prognosis. It accounts for 2% to 5% of all thyroid carcinomas and patients typically present with a rapidly growing anterior neck mass with aggressive symptoms. A 53-year-old male presented with diffuse neck swelling measuring 8x6 cm and right cervical lymph node measuring 2x2 cm since one month which was associated with dyspepsia and dyspnoea. Read More

    Evaluation of somatic genomic imbalances in thyroid carcinomas of follicular origin by CGH-based approaches.
    Minerva Endocrinol 2017 Sep 7. Epub 2017 Sep 7.
    Department of Medical Area, University of Udine, Udine, Italy -
    Introduction: Application of distinct technologies of cancer genome analysis has provided important information for the molecular characterization of several human neoplasia, including follicular cell-derived thyroid carcinoma. Among them, comparative genomic hybridization (CGH)-based procedures have been extensively applied to evaluate genomic imbalances present in these tumours, obtaining data leading to an increase in the understanding of their complexity and diversity.

    Evidence Acquisition: In this review, after a brief overview of the most commonly used CGH-based technichs, we will describe the major results deriving from the most influential studies in the literature which used this approach to investigate the genomic aberrations of thyroid cancer cells. Read More

    S Afr J Surg 2017 Sep;55(3):69
    University of Beira Interior, and Centro Hospitalar Cova da Beira, Hospital da Covilhã, and CICS-UBI Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior.
    Background: Iodine deficiency (ID) still affects over two billion people worldwide (266 million school aged children). Pathology patterns in ID include: increase in thyroid cancer, higher percentages of follicular and anaplastic cancers and inversion of the papillary/follicular thyroid cancer frequency ratio. China succeeded in eliminating ID through legislation introduced in 1987 aimed at availability of iodized salt countrywide and South Africa through legislation introduced in 1995. Read More

    Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
    J Korean Med Sci 2017 Oct;32(10):1721-1726
    Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
    Anaplastic thyroid carcinoma (ATC) is difficult to distinguish from other cancers, especially when its pathological features are atypical for ATC or when the tumor is totally undifferentiated and occurs after a considerable lapse of time, in an area remote from the original site of the tumor. Here, we present two patients (68-year-old man and 56-year-old woman) with rare manifestations of ATC, which were initially thought to be other malignancies. Immunohistochemical tests, using various markers, failed to provide information about the origin of these tumors. Read More

    [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Gan To Kagaku Ryoho 2017 Aug;44(8):695-697
    Dept. of Breast and Endocrine Surgery, Kanagawa Cancer Center.
    The 208 trial showed that lenvatinib has a significant antitumor effect on unresectable anaplastic thyroid cancer(ATC). Herein, we present a retrospective review of data from 7 patients with unresectable ATC who received lenvatinib in our hospital between May 2015 and October 2016. Two patients were men and 5 were women. Read More

    Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Sci Rep 2017 Aug 29;7(1):9749. Epub 2017 Aug 29.
    Cancer Science Institute (CSI) of Singapore, National University of Singapore, Singapore, Singapore.
    Anaplastic thyroid carcinoma (ATC) is one of the most lethal malignancies having no effective treatment. Exportin-1 (XPO1) is the key mediator of nuclear export of many tumor suppressor proteins and is overexpressed in human cancers. In this study, we examined the therapeutic potential of selinexor (XPO1 inhibitor) against human ATC cells both in vitro and in vivo. Read More

    Survival of Patients with Thyroid Cancer in Yazd, Iran
    Asian Pac J Cancer Prev 2017 08 27;18(8):2293-2297. Epub 2017 Aug 27.
    Department of Internal Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email:
    Background: Thyroid cancer is the most common endocrine related malignancy in the world. This cancer has increased during recent years in Iran and is the11th most common malignancy in Iranian population. Survival of patients with thyroid carcinoma in the different geographic areas within Iran is not clear. Read More

    Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
    Asian Pac J Cancer Prev 2017 08 27;18(8):2287-2291. Epub 2017 Aug 27.
    Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email:
    Background: Thyroidectomy, radioactive iodine therapy, chemotherapy, or their combination are treatments of choice for thyroid cancers. However, cancer stem cells (CSCs) may become resistant to therapy, and mutations in somatic genes affect radioiodine uptake. This study determined the effect of a phosphoinositide-3-kinase (PI3K) inhibitor on anaplastic thyroid CSCs. Read More

    Molecular Biomarkers of Anaplastic Thyroid Carcinoma.
    Curr Mol Med 2017 ;17(3):181-188
    Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran. Iran.
    Anaplastic thyroid carcinoma is the rarest but extremely aggressive thyroid cancer subtype. This neoplasia is composed of undifferentiated tumor cells with poor prognosis and resistant to common thyroid cancer therapy. Early stage identification of this cancer for prompt treatment is very vital. Read More

    Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer.
    Oncologist 2017 Oct 4;22(10):1149-1151. Epub 2017 Aug 4.
    Indiana University School of Medicine, Indiana University, Indianapolis, Indiana, USA
    Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 62-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab. Read More

    The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.
    J Endocrinol Invest 2017 Jul 31. Epub 2017 Jul 31.
    Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
    The most common endocrine malignancy is thyroid cancer, and researchers have made a great deal of progress in deciphering its molecular mechanisms in the recent years. Many of molecular changes observed in thyroid cancer can be used as biomarkers for diagnosis, prognosis, and therapeutic targets for treatment. MicroRNAs (miRNAs) are important parts in biological and metabolic pathways such as regulation of developmental stages, signal transduction, cell maintenance, and differentiation. Read More

    Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
    Clin Respir J 2017 Jul 29. Epub 2017 Jul 29.
    Department of Pathology, Kiang Wu Hospital, Macau Special Administrative Region, Macau, China.
    Objectives: We report the status of most common gene mutations in non-small cell lung carcinoma (NSCLC) in Macao, and explore the relationship between each gene mutation and clinicopathologic features and survival.

    Methods: EGFR, KRAS and BRAF mutations were detected by PCR in 122 cases of NSCLC. ALK translocation and MET amplification were detected by fluorescence in situ hybridization (FISH). Read More

    Size of thyroid carcinoma by histotype and variants: A population-based study in a mildly iodine-deficient area.
    Head Neck 2017 Oct 24;39(10):2095-2103. Epub 2017 Jul 24.
    Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
    Background: Data relating the size of thyroid cancer with histological types and variants are scarce.

    Methods: All incident thyroid cancer diagnosed between 2003 and 2012 in a mildly iodine-deficient area were derived from a population-based tumor registry. Undifferentiated/anaplastic thyroid cancer and incidental cases were excluded. Read More

    Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
    Mod Pathol 2017 Nov 21;30(11):1527-1537. Epub 2017 Jul 21.
    Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
    Thyroid papillary carcinoma is the most common endocrine neoplasm and generally carries a favorable prognosis. However, a small subset of papillary carcinomas transforms into anaplastic carcinoma, an undifferentiated cancer with a dismal prognosis. Recent studies using next-generation sequencing revealed the genomic landscape of papillary carcinoma and anaplastic carcinoma. Read More

    CCL2 is Modulated by Cytokines and PPAR-g in Anaplastic Thyroid Cancer.
    Anticancer Agents Med Chem 2017 Jul 19. Epub 2017 Jul 19.
    University of Pisa - Department of Clinical and Experimental Medicine Pisa. Italy.
    Background And Objective: Chemokine (C-C motif) ligand (CCL)2, the prototype Th2 chemokine, is secreted by tumor cells, and has growth promoting effects. Whether CCL2 protumorigenic activities will be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer.

    Methods: We tested in "primary human anaplastic thyroid carcinoma (ATC) cells" (ANA) versus "normal thyroid follicular cells" (TFC): a) CCL2 secretion basally, after IFN-g and/or TNF-a stimulation; b) PPARg activation by thiazolidinediones (TZDs), rosiglitazone or pioglitazone, on CCL2 secretion, and on proliferation and apoptosis in ANA. Read More

    Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
    Nat Rev Endocrinol 2017 Nov 14;13(11):644-660. Epub 2017 Jul 14.
    Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa.
    Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1-2% of all thyroid cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC often originates in a pre-existing thyroid cancer lesion, as suggested by the simultaneous presence of areas of differentiated or poorly differentiated thyroid carcinoma. Read More

    Anaplastic carcinoma of thyroid gland with widespread soft tissue metastasis: an unusual presentation.
    BMJ Case Rep 2017 Jul 13;2017. Epub 2017 Jul 13.
    Department of Oncology, Liaquat National Hospital and Medical College, Karachi, Pakistan.
    Anaplastic thyroid cancer is the rarest tumour of the thyroid gland, representing only 2% of clinically recognised thyroid cancers. The most common metastatic sites are lungs, followed by the intrathoracic and neck lymph nodes. We report the case of a 62-year-old woman who presented to our setting with multiple soft tissue nodules, thyroid mass, head swelling and weight loss. Read More

    Poorly Differentiated Thyroid Carcinoma: 10-Year Experience in a Southeast Asian Population.
    Endocrinol Metab (Seoul) 2017 Jun;32(2):288-295
    Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Philippine General Hospital, Manila, Philippines.
    Background: No previous studies have been published on poorly differentiated thyroid carcinoma (PDTC) in Southeast Asia.

    Methods: We included all adult PDTC patients diagnosed using the Turin criteria at the Philippine General Hospital from 2006 to 2015. The data collected included demographics, clinical presentation, histopathology, treatment, and outcomes. Read More

    Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.
    Curr Oncol 2017 Jun 27;24(3):e226-e232. Epub 2017 Jun 27.
    Department of Radiation Oncology, Princess Margaret Cancer Centre.
    Background: The radiotherapy (rt) volumes in anaplastic (atc) and differentiated thyroid carcinoma (dtc) are controversial.

    Methods: We retrospectively examined the patterns of failure after postoperative intensity-modulated rt for atc and dtc. Computed tomography images were rigidly registered with the original rt plans. Read More

    Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
    Int J Oncol 2017 Sep 4;51(3):760-770. Epub 2017 Jul 4.
    Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons, Mons, Belgium.
    Fine-needle aspiration (FNA) is the most commonly used pre-operative technique for diagnosis of malignant thyroid tumor. However, many benign lesions, with indeterminate diagnosis following FNA, are referred to surgery. Based on multifunctionality of the endogenous galectin-1, we aimed to assess its status for early diagnosis of thyroid cancer. Read More

    Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Cancer 2017 Nov 29;123(21):4114-4121. Epub 2017 Jun 29.
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
    Background: Patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for the treatment of radioactive iodine-refractory thyroid carcinoma, although it demonstrated low response rates (12.2%) as a single agent in the first-line setting. Read More

    A Case of a Rapidly Enlarging Neck Mass with Airway Compromise.
    J Clin Diagn Res 2017 May 1;11(5):OD14-OD16. Epub 2017 May 1.
    Division Director, Department of Internal Medicine, St. Barnabas Hospital, Bronx, New York, USA.
    Anaplastic Thyroid Carcinoma (ATC) is one of the most lethal tumours in humans, extremely rare in occurrence and very aggressive in nature. We hereby present a rare case of ATC with airway compromise. A 66-year-old male, presented complaining of a non-tender anterior neck mass rapidly increasing in size associated with dry cough, hoarseness and voice changes. Read More

    A rare presentation: A case report of osseous metaplasia and mature bone formation in a follicular adenoma of the thyroid.
    Int J Surg Case Rep 2017 17;37:83-86. Epub 2017 Jun 17.
    Surgical Oncologist, Department of Surgery, Texas Tech University School of Medicine, Amarillo, TX, USA. Electronic address:
    Introduction: Cases of multinodular goiter, thyroid hyperplasia, follicular adenoma, papillary thyroid carcinoma, and anaplastic thyroid carcinoma have been reported with histopathologic findings of osseous metaplasia (OM), bone marrow metaplasia (BMM), ectopic bone formation (EBF), ossification, and extramedullary hematopoiesis (EMH). To date no report of a follicular adenoma with OM and mature EBF in the absence of EMH has been reported in the English language.

    Presentation Of Case: 63-year-old woman with an incidental finding of thyroid nodule unable to be biopsied. Read More

    Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Thyroid 2017 Sep 24;27(9):1142-1148. Epub 2017 Jul 24.
    8 Medical Affairs, Oncology and Hematology, and Clinical Development, Specialty Medicine, Bayer Yakuhin Ltd. , Tokyo, Japan .
    Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC). An uncontrolled, open-label, multicenter, single-arm, Phase 2 clinical study was conducted to evaluate the safety and efficacy of sorafenib in Japanese patients with MTC and ATC. Read More

    [Clinical characteristics and prognosis of anaplastic thyroid carcinoma].
    Zhonghua Zhong Liu Za Zhi 2017 Jun;39(6):434-438
    Department of Head and Neck Surgery, Zhejiang Province Cancer Hospital, Hangzhou 310022, China.
    Objective: To investigate the clinical characteristics, treatment outcomes and prognostic factors in patients with anaplastic thyroid cancer. Methods: Clinical data of 56 patients with anaplastic thyroid cancer at Zhejiang Cancer Hospital from January 2006 to June 2016 were retrospectively reviewed and followed up. Results: Of the 56 patients, there were 24 male and 32 female. Read More

    1 OF 55